Investment Rating - The report maintains a BUY rating for BYD, indicating a potential return of over 15% over the next 12 months [3][7]. Core Views - Despite a miss in earnings for 4Q25, the report suggests that BYD could benefit from rising oil prices in overseas markets, which may lead to positive surprises in FY26 [1][7]. - The report emphasizes BYD's strong earnings quality and industry-leading technologies as foundations for net profit growth in FY26-27E [1][7]. - The projected revenue growth for BYD is expected to be 9% YoY in FY26 and 8% YoY in FY27, with gross profit margin remaining stable at 17.8% [7][9]. Financial Summary - Revenue projections for BYD are as follows: FY25A at RMB 803,965 million, FY26E at RMB 872,654 million, and FY27E at RMB 945,030 million, reflecting YoY growth rates of 3.5%, 8.5%, and 8.3% respectively [2][11]. - Net profit is projected to rise from RMB 32,619 million in FY25A to RMB 36,305 million in FY26E and RMB 43,828 million in FY27E, with YoY growth rates of -19.0%, 11.3%, and 20.7% respectively [2][11]. - The report notes a significant decrease in net profit per vehicle in 4Q25, which was approximately RMB 6,900, about RMB 100 lower than in 3Q25 [7]. Earnings and Valuation - BYD's operating cash flow for FY25 was RMB 59 billion, the lowest since FY21, attributed to shortened payable days [7]. - The report projects R&D expenses to grow at a slower pace of 3% YoY in FY26 and 2% YoY in FY27, indicating a more prudent approach to R&D spending [7]. - The target price for BYD shares is set at HK$125/RMB125, based on a P/E ratio of 23x for FY27E, reflecting a brighter outlook for overseas sales [3][7].

Investment Rating - The report maintains a "Buy" rating for China Biologic Products (1177 HK) [7] Core Views - The company reported a revenue growth of 10.3% year-on-year to RMB 31.83 billion for FY25, with innovative product revenue increasing by 26.2% to RMB 15.2 billion, accounting for 47.8% of total revenue [1] - Adjusted net profit grew by 31.4% year-on-year to RMB 4.54 billion, and if excluding dividends from Sinovac, the adjusted net profit still increased by 15% [1] - The company’s FY25 revenue was below expectations by 7.4% compared to the report's forecast and 3.9% compared to Bloomberg consensus, while adjusted net profit fell short by 27.5% and 9.0% respectively, mainly due to a milestone payment from Merck not being recognized as expected [1] - The company is expected to continue steady growth in FY26, driven by stable generic drug revenue and ongoing sales momentum from innovative drugs [1] Financial Summary - FY24A revenue is projected at RMB 28.87 billion, with a year-on-year growth of 10.2%, and FY25A revenue at RMB 31.83 billion, with a growth of 10.3% [2] - Adjusted net profit for FY26E is estimated at RMB 4.79 billion, reflecting a growth of 5.4% [2] - The adjusted earnings per share for FY26E is expected to be RMB 0.26, with a projected adjusted P/E ratio of 20.7 times [2] Target Price and Market Performance - The target price is set at HKD 8.70, down from the previous target of HKD 9.40, indicating a potential upside of 47.7% from the current price of HKD 5.89 [3] - The company has a market capitalization of HKD 110.5 billion and a 52-week price range of HKD 9.01 to HKD 3.34 [3] Shareholder Structure - Major shareholders include Xie Chengrun with 21.6% and Zheng Xiangling with 15.8% [4] Price Performance - The stock has shown a negative absolute return of -2.6% over the past month and -8.3% over the past three months [5]

Investment Rating - The report maintains a BUY rating for Innovent Biologics with a target price of HK$113.86, reflecting a potential upside of 33.2% from the current price of HK$85.50 [3]. Core Insights - Innovent Biologics reported its first-ever full-year net profit of RMB834 million for FY25, with revenue reaching RMB13.0 billion, representing a 38% year-over-year growth. Product sales increased by 45% year-over-year to RMB11.9 billion [1]. - The company is advancing its transition to a fully integrated global biopharma through strategic partnerships, including a collaboration with Takeda for IBI363 and a US$350 million upfront payment from Eli Lilly for early-stage assets [5]. - Innovent's product gross margin improved to 86.2% in 2H25, and the selling expense ratio decreased to 48.0% for FY25, despite a slight increase in 2H25 [1]. - The company has a strong pipeline with plans to advance at least five assets into global Phase 3 multi-regional clinical trials (MRCTs) by 2030, including IBI363 and IBI324, which is expected to disrupt the global retinal market [5]. - R&D expenses are projected to rise as global MRCTs advance, with a cash reserve of RMB24.3 billion as of the end of 2025, positioning Innovent well for its global ambitions [1]. Financial Summary - FY25 revenue was RMB13.0 billion, with a year-over-year growth of 38% and net profit of RMB834 million [1]. - Revenue projections for FY26, FY27, and FY28 are RMB16.6 billion, RMB20.9 billion, and RMB26.1 billion, respectively, with corresponding year-over-year growth rates of 27.6%, 25.7%, and 24.7% [2]. - The report indicates that net profit is expected to reach RMB2.1 billion in FY26, RMB3.4 billion in FY27, and RMB4.6 billion in FY28 [2]. Share Performance - The market capitalization of Innovent Biologics is approximately HK$148.36 billion, with an average turnover of HK$944 million over the past three months [3]. - The stock has shown a 1-month absolute performance of 0.5% and a 3-month performance of 5.9% [5].

Investment Rating - The report maintains a BUY rating for Akeso with a target price of HK$185.80, representing a 47.0% upside from the current price of HK$126.40 [3][9]. Core Insights - Akeso delivered strong product sales of RMB3.0 billion in FY25, reflecting a 52% year-over-year growth, closely aligning with previous estimates of RMB3.1 billion. This growth was primarily driven by the inclusion of cadonilimab and ivonescimab in the NRDL in January 2025 [1][2]. - Revenue growth is expected to accelerate further in FY26, supported by additional NRDL inclusions for major front-line indications [1]. - The company demonstrated operational leverage, with selling and R&D expenses as a percentage of product sales decreasing to 47% and 51%, respectively, from 49% and 56% in FY24 [1]. - Despite a reported net loss of RMB1.14 billion in FY25, Akeso maintains a robust balance sheet with RMB9.2 billion in cash and equivalents, providing a strong foundation for its late-stage clinical programs [1][2]. Financial Summary - Revenue projections for FY26 are estimated at RMB5.01 billion, with a year-over-year growth of 63.9%, followed by RMB8.68 billion in FY27 and RMB11.46 billion in FY28 [2][13]. - The net profit is projected to improve to RMB725.3 million in FY27 and RMB1.63 billion in FY28, after a loss of RMB733.7 million in FY26 [2][13]. - The gross profit margin is expected to normalize to 79% in FY25, down from 86% in FY24, due to price cuts associated with NRDL inclusions [1][2]. Clinical Development and Strategic Initiatives - Akeso is anticipating pivotal data readouts for ivonescimab, which has already met its primary PFS endpoint in a Phase 3 trial, showing a median PFS of 11.1 months compared to 6.9 months for the comparator [1][9]. - The company is advancing the global footprint of cadonilimab through pivotal trials, including a global Phase 2 trial for IO-resistant 2L HCC and a Phase 3 trial for 1L GC [1][9]. - Akeso's strategy includes the development of proprietary ADCs, with ongoing Phase 2 trials for HER3 ADC and TROP2/Nectin-4 ADC, aiming to evaluate combinatorial regimens with existing therapies [1][9].

Investment Rating - The report maintains a HOLD rating for China Tower, with a target price adjusted to HK$12.10 from the previous HK$13.10, indicating a potential upside of 13.2% from the current price of HK$10.69 [1][2]. Core Insights - China Tower's FY25 revenue increased by 2.7% YoY to RMB100.4 billion, aligning closely with estimates, while net profit rose 8.4% YoY to RMB11.6 billion, slightly above estimates [1]. - The improvement in net margin by 0.6 percentage points to 11.6% was primarily due to a lower depreciation and amortization (D&A) expense ratio [1]. - The tower business faced pressure with a 0.3% YoY decline in tower revenue, which constitutes 75% of total sales, as domestic telco capital expenditures (capex) decreased by 10.5% YoY [6]. - The report forecasts a continued decline in tower revenue by 1.5% YoY in 2026, reflecting flat site counts and ongoing pricing pressure [6]. - The DAS and Two Wings segments showed solid growth, with DAS revenue growing 9.5% YoY and Smart Tower revenue increasing 14.2% YoY [6]. - The company declared a full-year dividend per share (DPS) of RMB0.458, representing a 9.8% YoY increase, with a payout ratio of 77% [1]. Financial Summary - FY25 revenue was RMB100.4 billion, with projected revenues of RMB102.1 billion for FY26 and RMB103.3 billion for FY27, indicating a slowdown in growth [7]. - Net profit for FY25 was RMB11.6 billion, with projections of RMB15.4 billion for FY26 and RMB15.7 billion for FY27, reflecting a significant growth rate of 32.1% in FY26 [7]. - The EBITDA margin is expected to decline to 61.2% in FY26, down from 65.5% in FY25, indicating rising operational costs [8]. - The company’s total liabilities are projected to decrease from RMB132.7 billion in FY25 to RMB113.3 billion in FY26, improving the overall financial health [15].

Investment Rating - The report maintains a "Buy" rating for China Biopharmaceutical (1177 HK) [7] Core Views - The company reported a revenue growth of 10.3% year-on-year to RMB 31.83 billion for FY25, with innovative product revenue increasing by 26.2% to RMB 15.2 billion, accounting for 47.8% of total revenue [1] - Adjusted net profit grew by 31.4% year-on-year to RMB 4.54 billion, and if excluding dividends from Sinovac, the adjusted net profit still increased by 15% [1] - The company’s FY25 revenue was below expectations by 7.4% compared to the report's forecast and 3.9% compared to Bloomberg consensus, while adjusted net profit fell short by 27.5% and 9.0% respectively, mainly due to a milestone payment from Merck not being recognized as expected [1] - The company is expected to continue steady growth in FY26, driven by stable generic drug revenue and ongoing sales momentum from innovative drugs [1] Financial Summary - FY24A revenue is projected at RMB 28.87 billion, with a year-on-year growth of 10.2% - FY25A revenue is projected at RMB 31.83 billion, with a year-on-year growth of 10.3% - FY26E revenue is projected at RMB 36.13 billion, with a year-on-year growth of 13.5% [2] - Adjusted net profit for FY26E is expected to be RMB 4.79 billion, reflecting a year-on-year growth of 5.4% [2] - The adjusted earnings per share for FY26E is projected at RMB 0.26 [2] Target Price and Market Performance - The target price is set at HKD 8.70, down from the previous target of HKD 9.40, indicating a potential upside of 47.7% from the current price of HKD 5.89 [3] - The market capitalization is approximately HKD 110.5 billion [3] Shareholder Structure - The major shareholders include Xie Chengrun with 21.6% and Zheng Xiangling with 15.8% [4] Price Performance - The stock has shown a 1-month absolute return of -2.6% and a 3-month return of -8.3% [5]

Investment Rating - The report maintains a "BUY" rating for Baozun, with a target price raised to US$3.98 from US$3.81, indicating an upside potential of 82.6% from the current price of US$2.18 [2][19]. Core Insights - Baozun's 4Q25 results showed revenue of RMB3.2 billion, a 5.9% year-over-year increase, with non-GAAP net profit attributable to ordinary shareholders reaching RMB159.6 million, significantly up from RMB45.7 million in 4Q24 [1]. - The company aims for a non-GAAP operating profit target of at least RMB550 million by 2028, suggesting a compound annual growth rate (CAGR) of over 64% from 2025 to 2028, driven by margin expansion and strategic synergies between its e-commerce and brand management segments [1][11]. - Baozun's net cash position was approximately US$227 million at the end of 2025, compared to a market capitalization of US$127 million, indicating a strong financial position [1]. Financial Performance Summary - For FY25, Baozun reported revenue of RMB9.945 billion, with a projected revenue growth of 5.6% for FY26 and 5.3% for FY27 [9]. - The operating profit is expected to improve significantly, with projections of RMB181 million for FY26 and RMB356.6 million for FY27, reflecting a turnaround from a loss of RMB114.8 million in FY24 [9][16]. - The adjusted net profit is forecasted to reach RMB148 million in FY26 and RMB298 million in FY27, with a notable increase in profitability margins [9][17]. Segment Performance - Baozun E-commerce (BEC) generated revenue of RMB2.6 billion in 4Q25, up 2.5% year-over-year, with a non-GAAP operating profit increase of 43% year-over-year to RMB196 million [1]. - Baozun Brand Management (BBM) achieved revenue of RMB664 million in 4Q25, a 24% year-over-year increase, and turned a profit of RMB1.8 million compared to a loss of RMB34.2 million in 4Q24 [1][10]. - The gross profit margin for BEC expanded to 7.6% in 4Q25, supported by a 760 basis points increase in gross profit margin to 18.4% [8]. Valuation Metrics - The updated sum-of-the-parts (SOTP) valuation includes RMB1.35 billion for BEC based on a 5.0x 2026E EV/EBIT and RMB759 million for BBM based on a 0.4x 2026E EV/sales [14][15]. - The total equity value is estimated at RMB1.63 billion (approximately US$233 million), with a 60% holding discount applied to the group-level valuation [14][15].

Investment Rating - The report maintains a "BUY" rating for China Life, with a target price (TP) raised to HK$33 from the previous HK$31, implying a potential upside of 31.8% from the current price of HK$25.04 [3][10]. Core Insights - China Life reported a net profit of RMB154 billion for FY25, representing a 44.1% year-over-year increase, despite a net loss of RMB13.7 billion in 4Q25 due to fair value losses amid volatile market conditions [10][12]. - The company's net asset value increased by 16.8% year-over-year to RMB595.2 billion, with a return on equity (ROE) of 27.8%, up 6.2 percentage points from the previous year [10][12]. - The dividend per share (DPS) rose by 31.7% year-over-year to RMB0.86, exceeding expectations and indicating a payout ratio of 15.7% [10][12]. - Value of new business (VNB) surged by 35.7% year-over-year to RMB45.8 billion, driven by growth in both agency and bancassurance channels [10][12]. - Total investment assets grew by 12.3% year-over-year to RMB7.42 trillion, with a notable increase in the mix of stocks and equity funds [10][12]. Financial Performance Summary - For FY25, insurance revenue was RMB214.1 billion, a 2.9% increase from FY24, while insurance service expenses decreased by 17.6% to RMB148.7 billion [12][14]. - The net investment results for FY25 were RMB123.9 billion, a 31% increase year-over-year, although 4Q25 saw a negative result of RMB20.1 billion due to fair value contractions [10][12]. - The new business value margin (FYP basis) improved to 19.5% in FY25, with agency new business margin growing by 9.3 percentage points to 35% [10][12]. Share Performance and Market Data - The market capitalization of China Life is approximately HK$707.76 billion, with an average turnover of HK$2.13 billion over the last three months [4]. - The stock has experienced a 20.2% decline over the past month and a 12.0% decline over the past three months, but a 17.9% increase over the past six months [6].

Investment Rating - Initiate with BUY and target price of HK$200.00, representing a 100% upside from the current price of HK$100.00 [1][3]. Core Insights - PATEO CONNECT Technology (Pateo) is the third-largest supplier of smart cockpit domain controllers in China, with a sales volume of 0.9 million units and a market share of 7.3% in 2024 [1][9]. - The company has established strong partnerships with Qualcomm and Huawei, positioning itself as a leader in Snapdragon- and Kirin-based smart cockpit solutions [1][30]. - Pateo is exploring vehicle-related AI businesses, leveraging its software capabilities and partnerships with ICT giants [1][48]. - The smart cockpit market in China is projected to grow at a CAGR of 18.4% from 2024 to 2029, with Pateo expected to outperform this growth due to its integrated hardware-software solutions and new client acquisitions [7][51]. Financial Summary - Revenue projections show significant growth: FY23A at RMB 1,496 million, FY24A at RMB 2,557 million (YoY growth of 70.9%), and FY27E at RMB 8,487 million (YoY growth of 45.6%) [2]. - Gross margin is expected to improve from 11.8% in FY24A to 15.8% in FY27E, driven by a better product mix and economies of scale [2][82]. - The company anticipates reaching breakeven in adjusted operating profit by FY26E and a net profit of RMB 62 million in FY27E [2][82]. Market Position and Strategy - Pateo's smart cockpit solutions integrate hardware, software, and cloud-based systems, catering to various OEM needs, especially those with weaker software capabilities [9][10]. - The company has secured significant orders from new clients, including a South Korean automaker and Porsche, which are expected to contribute substantially to revenue growth in FY26-27E [78][80]. - Pateo's AI application revenue is projected to reach RMB 0.7 billion in FY26E and RMB 1.2 billion in FY27E, indicating potential undervaluation by investors [7][96]. Industry Analysis - The smart cockpit market is rapidly evolving, with a shift from traditional systems to advanced smart cockpit solutions, driven by consumer demand for enhanced in-car experiences [51][56]. - China's smart cockpit solutions market is expected to grow from RMB 129.0 billion in 2024 to RMB 299.5 billion in 2029, with Pateo positioned to capture a larger share due to its innovative offerings [57][60]. - The intelligent vehicle connectivity market is also expanding, with Pateo's revenue from this segment projected to grow significantly as OEMs increasingly outsource connectivity solutions [69][72].

Company Analysis - Meituan (3690 HK) reported 4Q25 revenue of RMB 92.1 billion, a year-on-year increase of 4.1%, aligning with Bloomberg consensus expectations. The adjusted net loss was RMB 15.1 billion, at the lower end of the previously warned range of RMB 15.1 billion to RMB 16.1 billion. The core local commerce (CLC) business is believed to have reached a bottom in profitability due to regulatory guidance promoting healthier industry practices and a focus on core competencies among participants [2][6] - The operating loss of Meituan's core local commerce business narrowed by 29% quarter-on-quarter in 4Q25, with expectations for a further 58% reduction to RMB 4.2 billion in 1Q25 [2] - Weichai Power (2338 HK) experienced an unexpected 4% decline in net profit for 2025, totaling RMB 10.9 billion, which is 12% lower than consensus expectations. The 4Q25 net profit fell by 32% year-on-year to RMB 2 billion, primarily due to a 3.9 percentage point drop in gross margin [6][7] - Despite the weak performance, Weichai Power's transition towards electric power business remains positive, with electric-related engine sales expected to increase from 12% in 2024 to 14% in 2025. The target price for Weichai Power has been adjusted to HKD 30.5 and RMB 28.7, reflecting an increase in the EV/EBITDA target multiple to 11 times [6][7] - Binhai Service (3316 HK) reported a 14.1% year-on-year revenue growth to RMB 4.1 billion for the 2025 fiscal year, although this was slightly below consensus expectations. Net profit grew by 12.1% to RMB 880 million, also below expectations. The company has reduced its reliance on the parent company, with an increase in property fee collection rates and average property fees [6][7] - The average property fee rose to RMB 4.2 per square meter per month, with 14 projects completing fee increase contracts in 2025. This performance is attributed to the company's high-end positioning and focus on project concentration [7][8] Industry Overview - The global market has shown a downward trend, with major indices such as the Hang Seng Index falling by 1.89% and the S&P 500 declining by 1.74%. The technology sector, particularly in the US, has faced significant pressure, with the Nasdaq dropping by 2.38% [3][5] - The A-share market also experienced declines, with the Shanghai Composite Index down by 1.09% and the ChiNext Index down by 1.34%. The market is influenced by sectors such as computing, non-bank financials, and telecommunications leading the declines, while coal, oil, and banking sectors showed some resilience [5] - The global bond market remains under pressure, with US Treasury yields rising across the board, reflecting concerns over economic resilience and inflation. The 10-year Treasury yield reached 4.41% [5]